RegulatoryMay 22, 2026, 04:31 PM
Greenwich LifeSciences Receives Nasdaq Non-Compliance Notice
AI Summary
Greenwich LifeSciences announced it received a notification from Nasdaq on May 20, 2026, regarding non-compliance with Listing Rule 5250(c)(1). This non-compliance is due to the company's failure to timely file its Quarterly Report on Form 10-Q for the three months ended March 31, 2026. The notice currently has no immediate effect on the listing or trading of the company's common stock on the Nasdaq Capital Market.
Key Highlights
- Received Nasdaq notification on May 20, 2026, for non-compliance.
- Non-compliance due to unfiled Q1 2026 Form 10-Q.
- Violates Nasdaq Listing Rule 5250(c)(1) for timely financial reports.
- No immediate impact on GLSI's stock listing or trading.
- Company is a clinical-stage biopharmaceutical firm.
- Focused on Phase III FLAMINGO-01 trial for GLSI-100.
Price Impact
More from GLSI